NCT06556602 Methadone Patient Access to Collaborative Treatment
| NCT ID | NCT06556602 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Arizona |
| Condition | Opioid Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,080 participants |
| Start Date | 2026-02-05 |
| Primary Completion | 2029-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,080 participants in total. It began in 2026-02-05 with a primary completion date of 2029-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The trial of Methadone Patient Access to Collaborative Treatment (MPACT) will establish the impact of the intervention on patient outcomes of methadone treatment retention and in treatment overdose. It will also establish the impact of patient and staff trauma symptoms and clinic practice change on MPACT intervention implementation.
Eligibility Criteria
Inclusion Criteria: * Staff providing methadone treatment services at the enrolled opioid treatment programs Exclusion Criteria: * Patients receiving methadone treatment at the enrolled opioid treatment programs
Frequently Asked Questions
Who can join the NCT06556602 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Opioid Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06556602 currently recruiting?
Yes, NCT06556602 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Arizona to inquire about joining.
Where is the NCT06556602 trial being conducted?
This trial is being conducted at Tucson, United States.
Who is sponsoring the NCT06556602 clinical trial?
NCT06556602 is sponsored by University of Arizona. The trial plans to enroll 1,080 participants.